Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does candesartan benefit patients with heart failure?

Nature Clinical Practice Cardiovascular Medicine volume 3, pages 250–251 (2006)Cite this article

boxed-textDemers C et al. (2005) Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA 294: 1794–1798

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Yusuf S et al. (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145–153

    Article  CAS  Google Scholar 

  2. Granger CB et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362: 772–776

    Article  CAS  Google Scholar 

  3. Cohn JN and Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667–1675

    Article  CAS  Google Scholar 

  4. Pitt B et al. (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582–1587

    Article  CAS  Google Scholar 

  5. Pfeffer MA et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893–1906

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Internal Medicine,

    Christian Torp-Pedersen & Lars Køber

  2. Associate Professor of Internal Medicine at the University of Copenhagen, Copenhagen, Denmark

    Christian Torp-Pedersen & Lars Køber

Authors
  1. Christian Torp-Pedersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lars Køber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Torp-Pedersen.

Ethics declarations

Competing interests

C Torp-Pedersen and L Køber have given presentations at industry-sponsored symposia, and both were on the steering committee of the TRACE study. L Køber was on the steering committee of the VALIANT study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Torp-Pedersen, C., Køber, L. Does candesartan benefit patients with heart failure?. Nat Rev Cardiol 3, 250–251 (2006). https://doi.org/10.1038/ncpcardio0536

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0536

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing